| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SJ.IJIR.3901416 |
| P698 | PubMed publication ID | 16292333 |
| P2093 | author name string | Dayanir Y | |
| Koçak I | |||
| Dündar M | |||
| Dündar SO | |||
| Topaloğlu A | |||
| P2860 | cites work | Effect of sildenafil citrate (Viagra) on the ocular circulation | Q30671807 |
| Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group | Q34747116 | ||
| Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function | Q39650606 | ||
| Role of nitric oxide in the physiology of erection | Q40529459 | ||
| Possible role for nitric oxide releasing nerves in the regulation of ocular blood flow in the rat | Q42014464 | ||
| Nitric oxide synthase immunoreactivity and NADPH diaphorase staining are co-localised in neurons closely associated with the vasculature in rat and human retina | Q42479272 | ||
| Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction | Q42679993 | ||
| Effect of sildenafil on ocular haemodynamics | Q43839594 | ||
| Effects of sildenafil on ocular perfusion demonstrated by color Doppler ultrasonography | Q44770303 | ||
| The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. | Q50951063 | ||
| Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. | Q53348475 | ||
| Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction | Q56067856 | ||
| Control of regional blood flow by endothelium-derived nitric oxide | Q68767825 | ||
| Sildenafil, a novel effective oral therapy for male erectile dysfunction | Q71547678 | ||
| Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro | Q73457349 | ||
| Sildenafil and ocular perfusion | Q73848990 | ||
| Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes | Q74582058 | ||
| Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells | Q74586615 | ||
| Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men | Q77492625 | ||
| Retinal side-effects of sildenafil | Q78019271 | ||
| P433 | issue | 3 | |
| P921 | main subject | hemodynamics | Q1642137 |
| P304 | page(s) | 282-286 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | International Journal of Impotence Research | Q15749221 |
| P1476 | title | Effect of sildenafil on ocular hemodynamics in 3 months regular use. | |
| P478 | volume | 18 |
| Q35112853 | Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers |
| Q89965037 | Ocular Side Effects of Sildenafil That Persist Beyond 24 h-A Case Series |
| Q37119486 | Ocular perfusion pressure and color Doppler imaging of the external ophthalmic artery of rabbits treated with sildenafil citrate |
| Q28067059 | Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction |
| Q37016354 | Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link? |
| Q26861763 | Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma |
| Q40104607 | Sildenafil dilates ophthalmic artery in type 2 diabetic patients |
| Q34918423 | Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date |
Search more.